USPTO serial 79046715
PATRYS
Reviewed by CopyMark Law Group
Reg. 3612574Status 706Registered
- Filing date
- Status date
- Registration date
- Apr 28, 2009
- Examiner
- STEPHENS, SONYA B
- Law office
- GENERIC WEB UPDATE
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with PATRYS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
South Melbourne, AU
MELBOURNE VIC 3000, AU
MELBOURNE VIC 3000, AU
AU
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mainak H. Mehta
Mainak H. Mehta Procopio, Cory, Hargreaves & Savitch LLP525 B. Street, Suite 2200,San Diego, CA 92101UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and biotechnological preparations and substances for human medicinal purposes, namely, for the treatment of cancers and autoimmune diseases; [ veterinary preparations and substances for animal medicinal purposes, namely, for the treatment of cancers and autoimmune diseases; ] diagnostic preparations for medical use and reagents for medical use, namely, for diagnosis of human diseases, such as cancer and autoimmune diseases; [ pharmaceutical and biotechnological preparations, namely, antibodies for the treatment of cancers and autoimmune diseases; ] pharmaceutical and biotechnological preparations, namely, antibody fragments and antibody conjugates for the treatment of cancers and autoimmune diseases; [ pharmaceutical and biotechnological preparations for the reconstruction and repair of antibodies for use in the field of cancers and autoimmune diseases; ] monoclonal antibodies for medical and veterinary use, namely, reagents for the diagnosis and prognosis of human and animal diseases, such as cancer and autoimmune diseases; proteins for medical use, namely, for detecting antibodies; clinical medical reagents, namely, reagents for use in the development of monoclonal antibodies; proteins for medical use, namely, for binding antibodies; [ reagents for veterinary use, namely, reagents for the development of monoclonal antibodies; vaccines; vaccines against cancer, viral infection and bacterial infection, vaccines for human use; vaccine adjuvants; ] medical and veterinary diagnostic reagents, namely, reagents for use in tests for the diagnosis and prognosis of human and animal diseases, such as cancer and autoimmune diseases; reagents for research purposes, namely, diagnostic reagents for medical research applications; cells for medical or clinical use, namely, recombinant human protein production cell lines; proteins for medical use in the field of recombinant DNA technology; biological reagents for medical purposes in the field of molecular biology | ACTIVE | — |
| 042 | Scientific research and development, clinical research and scientific advisory and consultancy services all in relation to antibody production; drug discovery; [ research and development of vaccines, namely, vaccine screening; ] scientific research advisory services relating to diagnostic products for diagnosing cancers and autoimmune diseases; [ diagnostic testing services, namely, providing reagent sample testing and diagnostic services for others in the field of science; ] medical research services; scientific research for medical purposes; pharmaceutical research services; scientific research advisory services comprising the preparation of reports relating to the performance and analysis of research and the outcomes of research in the field of pharmaceuticals and biotechnology; biochemical, chemical, microscopy, spectroscopy, physiological, histological, and electrical analysis of biological tissues for medical research; scientific research and development services for the production of antibodies; scientific research and development services for the discovery and development of proteins that bind to antibodies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PATRYS LIMITED
- Other trademarks owned by PATRYS LIMITED
- Other trademarks owned by PATRYS LIMITED
- Other trademarks owned by Patrys Pty Ltd
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named PATRYS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 18, 2020 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Dec 25, 2019 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Apr 25, 2019 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Apr 25, 2019 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Apr 9, 2019 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Apr 28, 2018 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Jun 29, 2017 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Jul 1, 2016 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 11, 2015 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Aug 19, 2015 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Aug 19, 2015 | INPC | INVALIDATION PROCESSED | — |
| Jul 6, 2015 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Nov 6, 2014 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Nov 6, 2014 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Oct 1, 2014 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 22, 2014 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Apr 2, 2014 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 29, 2013 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 12, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 11, 2011 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Aug 10, 2009 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 10, 2009 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 28, 2009 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 28, 2009 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 6, 2009 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Mar 13, 2009 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Feb 10, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 21, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| Jan 8, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 27, 2008 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Dec 19, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 18, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 18, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 16, 2008 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 16, 2008 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Dec 16, 2008 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Dec 16, 2008 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Dec 5, 2008 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Oct 31, 2008 | GNS1 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | — |
| Oct 31, 2008 | GNCF | CONTINUATION OF FINAL REFUSAL E-MAILED | — |
| Oct 31, 2008 | CNCF | ACTION CONTINUING A FINAL - COMPLETED | — |
| Sep 16, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 15, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 15, 2008 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Sep 15, 2008 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 15, 2008 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 23, 2008 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 21, 2008 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 6, 2008 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| May 6, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 1, 2008 | ALIE | ASSIGNED TO LIE | — |
| Apr 29, 2008 | PAPER RECEIVED | — | |
| Feb 8, 2008 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 16, 2008 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 16, 2008 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 16, 2008 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 15, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 21, 2007 | NWAP | NEW APPLICATION ENTERED | — |
| Dec 20, 2007 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |